Longeveron INC Form 4 insider transactions

Longeveron Inc.'s CTO and SVP of CMC, Devin Blass, reported a future disposition of 4,599 Class A Common Stock shares on July 1, 2025, to cover tax obligations related to a restricted stock unit award.

Longeveron Inc.'s CEO, Mohamed Wa'el Ahmed Hashad, disposed of 13,146 shares of Class A Common Stock at $1.28 per share on July 1, 2025, to cover tax obligations related to a restricted stock unit award vesting.

Longeveron Inc.'s Chief Financial Officer, Lisa Locklear, reported the withholding of 7,431 shares of Class A Common Stock on July 1, 2025, to cover tax obligations related to the vesting of a restricted stock unit award.

Longeveron Inc.'s General Counsel and Secretary, Paul T. Lehr, reported the disposition of 1,562 shares of Class A Common Stock at $1.28 per share to cover tax obligations related to a restricted stock unit vesting.

Longeveron Inc.'s Chief Medical Officer, Nataliya Agafonova, reported a future disposition of 7,431 shares of Class A Common Stock to cover tax obligations related to a restricted stock unit award vesting, effective July 1, 2025.

Longeveron Inc.'s Chief Scientific Officer, Director, and 10% Owner, Joshua Hare, reported the acquisition of 49,219 stock options with an exercise price of $1.28, which vested immediately on July 1, 2025.

Longeveron Inc.'s General Counsel, Paul T. Lehr, reported the award and vesting of 163,043 restricted stock units and the subsequent sale of 64,158 shares to cover tax obligations, with all transactions scheduled for June 23, 2025, an unusual future date relative to the filing date.

Longeveron Inc. has filed an amended Form 4 to correct the transaction date for a stock option grant to Chief Scientific Officer Joshua Hare and confirm shareholder approval for an increase in shares available under its 2021 Incentive Award Plan.

Longeveron Inc. has granted 184,878 stock options to Chief Scientific Officer Joshua Hare, which will fully vest on July 1, 2025, following shareholder approval of an increase in shares available under the company's incentive plan.

Longeveron Inc. Director and 10% owner, Rock Soffer, reported the sale of 21,000 shares of Class A Common Stock over two days in late May 2025, reducing his direct beneficial ownership to 209,034 shares.

Longeveron Inc. Director Rock Soffer has reported the sale of 2,000 shares of the company's Class A Common Stock at a price of $1.32 per share, as disclosed in a recent SEC Form 4 filing.

Joshua Hare, Chief Scientific Officer and Director at Longeveron Inc., sold 5,250 shares of Class A Common Stock at a weighted average price of $1.4033 on May 16, 2025.

Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Lisa Locklear, CFO of Longeveron Inc., reports the withholding of shares to cover tax obligations related to a restricted stock unit vesting.

Longeveron Inc. CEO Mohamed Wa'el Ahmed Hashad disposed of 13,384 shares of Class A Common Stock on April 1, 2025, to satisfy tax obligations related to a restricted stock unit award.

Paul T. Lehr, General Counsel and Secretary of Longeveron Inc., reports the disposal of 1,599 shares to cover tax obligations related to vesting restricted stock units.

Joshua Hare, Chief Scientific Officer of Longeveron Inc., reports the acquisition of stock options exercisable for 71,254 shares of common stock.

Longeveron's Chief Medical Officer, Nataliya Agafonova, sold 6,120 shares of Class A Common Stock to cover tax obligations related to a restricted stock unit vesting.

Longeveron's CEO, Mohamed Wa'el Ahmed Hashad, sold 10,827 shares of Class A Common Stock to cover tax obligations related to a restricted stock unit vesting.

Longeveron's Chief Financial Officer, Lisa Locklear, sold 6,120 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Paul T. Lehr, General Counsel and Secretary of Longeveron Inc., reports the disposal of 1,205 shares to cover tax obligations related to vesting restricted stock units.

A Longeveron Inc. director, Khoso Baluch, sold 1,250 shares of Class A Common Stock at $2.0705 per share, following a correction of a previous filing error regarding a stock split.

Lisa Locklear, CFO of Longeveron Inc., reports the disposal of 5,316 shares to cover tax obligations related to vesting restricted stock units.

Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Paul T. Lehr, General Counsel and Secretary of Longeveron Inc., reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Longeveron's CEO, Mohamed Hashad, reports a transaction involving the withholding of shares to cover tax obligations related to a restricted stock unit award.

Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., reports acquisition of restricted stock units and stock options, as well as shares withheld for tax obligations.

Lisa Locklear, CFO of Longeveron Inc., reports the acquisition of 174,750 shares of Class A Common Stock and disposal of 14,035 shares to cover tax obligations.

Longeveron CEO Mohamed Hashad reported the acquisition of 311,250 shares of Class A Common Stock through a restricted stock unit (RSU) award and the disposal of 39,248 shares to cover tax obligations.

General Counsel and Secretary Paul T. Lehr reports acquisition of restricted stock units and stock options, as well as shares withheld for tax obligations.